MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics


0.00 (0.00%)

POWR Rating

Component Grades













Add MNPR to Watchlist
Sign Up

Industry: Biotech



in industry

MNPR Stock Price Chart Interactive Chart >

Price chart for MNPR

MNPR Price/Volume Stats

Current price $2.25 52-week high $6.98
Prev. close $2.25 52-week low $1.70
Day low $2.17 Volume 1,993
Day high $2.25 Avg. volume 10,119
50-day MA $2.39 Dividend yield N/A
200-day MA $3.66 Market Cap 28.40M


Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

MNPR Latest News Stream

Event/Time News Detail
Loading, please wait...

MNPR Latest Social Stream

Loading social stream, please wait...

View Full MNPR Social Stream

Latest MNPR News From Around the Web

Below are the latest news stories about Monopar Therapeutics that investors may wish to consider to help them evaluate MNPR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | February 22, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | February 18, 2022

Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Pacira Pharmaceuticals (PCRX) and Monopar Therapeutics Inc (MNPR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Pacira Pharmaceuticals (PCRX – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report). Masimo (MASI) BTIG analyst Marie Thibault maintained a Hold rating on Masimo today. The company's shares closed last Tuesday at $228.84. According to TipRanks.

Brian Anderson on TipRanks | February 16, 2022

Monopar Announces Clinical and Preclinical Program Updates

Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced program updates across its pipeline and anticipated 2022

Yahoo | February 15, 2022

Maxim Group Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) on February 2 and set a price target of $8.00. The company's shares closed last Friday at $2.76, close to its 52-week low of $2.36. According to, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $16.67.

Christine Brown on TipRanks | February 6, 2022

Read More 'MNPR' Stories Here

MNPR Price Returns

1-mo -5.86%
3-mo -29.69%
6-mo -53.61%
1-year -61.01%
3-year N/A
5-year N/A
YTD -29.91%
2021 -47.55%
2020 -63.13%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8488 seconds.